Abstract
Current and emerging PET platforms will enhance the ability to evaluate metastatic lesions in mCRPC. It remains unclear how the evolution of new lesions on more sensitive scans can improve clinical care as all current therapeutics were developed using CT Scan and Tc99m-MDP (Tc99) bone scans. 18F-Sodium Fluoride (NaF) PET imaging has increased sensitivity for bone lesions relative to Tc99. Here we test a semi-automated method of assessing NaF PET using a novel technology.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
